Experts and national consultants’ recommendations regarding management of patients treated for migraine with comorbid depression. Diagnosis. Therapeutic strategies. Part 2
Author(s) -
Adam Stȩpień,
Agnieszka Słowik,
Izabela Domitrz,
Wojciech Kozubski,
Konrad Rejdak,
J Rózniecki,
Jarosław Woroń,
Katarzyna Wachowska,
Piotr Gałecki
Publication year - 2021
Publication title -
psychiatria polska
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.414
H-Index - 22
eISSN - 2391-5854
pISSN - 0033-2674
DOI - 10.12740/pp/onlinefirst/139596
Subject(s) - migraine , medicine , depression (economics) , psychiatry , economics , macroeconomics
Depressive disorders are currently diagnosed based on the ICD-10 and DSM-5 diagnostic criteria and include axial depressive symptoms and additional symptoms that must coexist for at least two weeks. Migraine is diagnosed based on the International Classification of Headache Disorders. It is generally divided into migraine with and without aura, and with regard to the frequency of attacks into episodic and chronic migraine. The therapeutic strategy in the treatment of depression is pharmacotherapy combined with psychotherapy, whereas in the treatment of migraine the strategy depends on the frequency of headache attacks (episodic migraine vs. chronic migraine) and comorbidities. A novelty is the introduction of monoclonal antibodies directed against CGRP or the receptor of CGRP. There are numerous reports which indicate specific usefulness of monoclonal antibodies that modify the action of CGRP in the treatment of migraine in people suffering from depression.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom